BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gouldthorpe O, Catto-Smith AG, Alex G, Simpson D. Loss of response to long-term infliximab therapy in children with Crohn's disease. Pharmaceuticals (Basel) 2013;6:1322-34. [PMID: 24275852 DOI: 10.3390/ph6101322] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 van Rheenen H, van Rheenen PF. Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies. Pediatr Gastroenterol Hepatol Nutr 2020;23:121-31. [PMID: 32206624 DOI: 10.5223/pghn.2020.23.2.121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Joosse ME, Samsom JN, van der Woude CJ, Escher JC, van Gelder T. The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:2214-21. [PMID: 26284297 DOI: 10.1097/MIB.0000000000000420] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
3 Dupont-Lucas C, Sternszus R, Ezri J, Leibovitch S, Gervais F, Amre D, Deslandres C. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease. J Crohns Colitis 2016;10:795-804. [PMID: 26822611 DOI: 10.1093/ecco-jcc/jjw038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
4 Carnovale C, Maffioli A, Zaffaroni G, Mazhar F, Battini V, Mosini G, Pozzi M, Radice S, Clementi E, Danelli P. Efficacy of Tumour Necrosis Factor-alpha therapy in paediatric Crohn's disease patients with perianal lesions: a systematic review. Expert Opin Biol Ther 2020;20:239-51. [PMID: 31971447 DOI: 10.1080/14712598.2020.1718096] [Reference Citation Analysis]
5 Day AS, Gulati AS, Patel N, Boyle B, Park KT, Saeed SA. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:361-8. [PMID: 29210919 DOI: 10.1097/MPG.0000000000001850] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
6 Mazhar F, Battini V, Pozzi M, Invernizzi E, Mosini G, Gringeri M, Capuano A, Scavone C, Radice S, Clementi E, Carnovale C. Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. BioDrugs 2020;34:649-68. [PMID: 32940873 DOI: 10.1007/s40259-020-00444-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nuti F, Fiorino G, Danese S. Adalimumab for the treatment of pediatric Crohn’s disease. Expert Review of Clinical Immunology 2015;11:963-72. [DOI: 10.1586/1744666x.2015.1072048] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
8 Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:951-961. [PMID: 25723615 DOI: 10.1097/mib.0000000000000245] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
9 Burgess CJ, Reilly C, Steward-harrison L, Balouch F, Lewindon PJ. Utility of proactive infliximab levels in paediatric Crohn’s disease. Arch Dis Child 2019;104:251-5. [DOI: 10.1136/archdischild-2018-315100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Kierkus J, Szymanska E, Oracz G, Wiernicka A, Dadalski M. Profile of infliximab in the treatment of pediatric Crohn's disease. Pediatric Health Med Ther 2015;6:79-85. [PMID: 29388577 DOI: 10.2147/PHMT.S64943] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]